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Abstract. Exenatide is a glucagon-like peptide-1 receptor agonist with both immediate-
and extended-release (ER) formulations that are approved for the treatment of type 2
diabetes mellitus. Long-term exposure from the ER formulation is achieved through slow
peptide release from a degradable microsphere formulation. The goal of this analysis was to
develop a pharmacokinetic model for the ER formulation following single and once-weekly
multiple-dose administration. Pharmacokinetic data were collected from two clinical
trials—one that evaluated single-dose administration of 2.5, 5, 7, and 10 mg of ER exenatide
and a second that included weekly administration of 0.8 and 2 mg for 15 weeks. A population
pharmacokinetic model, describing 1586 exenatide concentrations from 64 patients, was
developed in the nonlinear mixed-effects modeling software program NONMEM. Pharma-
cokinetics of the ER formulation was described by a two-compartment model with linear and
nonlinear elimination. The complex absorption proﬁle was quantiﬁed using three simulta-
neous processes: a ﬁrst-order process characterizing a rapid initial release and two series of
transit compartments to describe the second (∼3 weeks postinjection) and third phases of
drug release (∼7 weeks postinjection). Estimation of the combined single- and multiple-dose
data adequately described the rise to steady-state (∼8–10 weeks) and decline to undetectable
concentrations that occurred about 10 weeks after treatment cessation. Thus, a population-
based pharmacokinetic model was developed that provides a platform for future pharma-
codynamic analyses with the ER formulation of exenatide.
KEY WORDS: exenatide; pharmacokinetics; subcutaneous extended release; transit compartments; type
2 diabetes mellitus.
INTRODUCTION
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor
agonist that has been shown to improve glycemic control
among patients with type 2 diabetes mellitus (1, 2). Exenatide
is available either as a twice-daily, immediate-release (IR)
formulation (Byetta®; AstraZeneca, Wilmington, DE), or as a
once-weekly, extended-release (ER) formulat ion
(Bydureon®; AstraZeneca). The exenatide peptide elicits its
glycemic response through multiple mechanisms of action,
including glucose-dependent insulin secretion (ﬁrst and
second phase) (3), slowing of gastric emptying (4), increased
satiety, and suppression of glucagon (1, 3–5). The pharmaco-
kinetics (PK), safety, and efﬁcacy of the IR formulation have
been extensively documented (4, 6–16). A retrospective
population PK analysis describing a wide range of exenatide
concentrations associated with multiple routes of administra-
tion identiﬁed signiﬁcant covariates that inﬂuence systemic
exposure of the IR formulation, including renal function on
systemic clearance and body weight on the volume of
distribution (Cirincione B, Mager DE. Population pharmaco-
kinetics of exenatide. Manuscript accepted). For a typical
patient, both the absorption and elimination of the IR
formulation following subcutaneous (SC) administration are
rapid, with peak concentrations occurring approximately 2 h
postdose, followed by a terminal half-life of about 2.4 h (1).
Thus, the IR formulation is administered twice daily, within
60 min prior to the morning and evening meals, to achieve
effective daily glycemic control (1). In order to improve
patient compliance and further improve glycemic beneﬁt,
new drug formulations are under development with the
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potential to extend drug release, resulting in an increased
duration of exenatide exposure and effects.
The ER formulation of exenatide was developed to
provide patients with long-term exenatide exposure allowing
for a once-weekly dosing interval (2). This formulation is
based on dispersing exenatide in a structural matrix com-
posed of medical-grade biodegradable poly(D,L-lactide-co-
glycolide) (PLGA) polymer (17). After SC administration,
the PLGA polymer undergoes hydrolysis in the SC space
leading to a continuous release of exenatide (17, 18). The
release of exenatide from the PLGA polymers following a
single injection results in a total duration of drug exposure of
10–12 weeks (18). The concentration–time proﬁle of the ER
formulation after a single SC injection is characterized by
three distinct phases. Phase 1 is an initial release of exenatide
that is loosely bound to the surface of the microsphere, which
is readily released upon hydration of the microsphere and
occurs within the ﬁrst 24 h after SC administration. Following
this initial release, the PLGA polymer is slowly hydrolyzed
leading to a slow release of exenatide, culminating in a second
peak occurring approximately 2 weeks after an SC dose.
During the third phase, the microspheres fully hydrolyze and
all the remaining drug is slowly released in the SC space to be
absorbed into the systemic circulation, producing a third peak
that appears in the concentration–time proﬁle approximately
7 weeks postdose. The microspheres themselves are degraded
to water and CO2 in the SC space and are not absorbed intact
into the circulation (17). Once released from the micro-
spheres and absorbed into the circulation, the exenatide
peptide follows the same distribution and elimination prop-
erties as the IR formulation (17).
The aim of this analysis was to develop a population PK
model for the ER formulation of exenatide following both
single- and multiple-dose administration. Such a model must
account for each phase of drug release, providing a quanti-
tative platform for assessing the factors inﬂuencing the time
to steady-state and average plasma drug concentrations
following multiple-dose administration. The ﬁnal model may
be used to test hypotheses pertaining to the inﬂuence of
intrinsic factors on components of the concentration–time
proﬁle and ultimate pharmacodynamic responses, as well as
for simulating alternative dosing regimens.
MATERIALS AND METHODS
Study Design
PK data for model development were obtained from two
clinical trials (18). The ﬁrst study was a phase II, randomized,
double-blind, placebo-controlled 12-week trial in patients
with type 2 diabetes using a single dose of the ER formulation
at doses of 2.5, 5, 7, and 10 mg, which resulted in measurable
exenatide concentrations for approximately 9–11 weeks post-
injection (18). The study term visit was considered uninfor-
mative as it consisted of primarily undetectable exenatide
concentrations and thus was not included. Exenatide plasma
concentrations were assessed at 23 time points over the
duration of the trial. Speciﬁc collection times included a rich
sampling period (0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 30, 36, and
48 h postinjection) to capture initial drug release, followed by
sampling at 11 additional time points (collected at weekly
visits from weeks 1 to 11). A total of 1054 concentration
measurements from 47 patients were collected in the single-
dose study. Data from six patients were excluded due to one
or more of the following reasons: patient was determined not
evaluable, more than 90% of the concentrations were assayed
as below the limit of quantiﬁcation (BLQ), or the proﬁle
signiﬁcantly deviated from the anticipated population proﬁle.
There were a total of 887 plasma exenatide concentrations
from 41 patients collected from this single-dose study. The
second study was a phase II, randomized, double-blind,
placebo-controlled trial that evaluated two dose levels of
ER exenatide (0.8 and 2 mg) administered once weekly for
15 weeks (18). Exenatide plasma concentrations were mea-
sured at 22 time points across the 15-week treatment period
capturing the initial release and the rise to steady-state
conditions, followed by an additional 8 samples during a 12-
week washout period. Concentration–time data from 31
patients enrolled in this phase II trial were available, and
eight patients were excluded due to incomplete dosing
information. There were a total of 699 plasma exenatide
concentrations collected from 23 patients with complete
dosing in this multiple-dose study. Overall, a total of 1586
exenatide concentrations from 64 patients were available for
model development.
Data from 119 patients (408 plasma exenatide concen-
trations) enrolled in a phase III trial evaluating 2 mg of ER
exenatide for 24 weeks were used as an external validation
dataset (19). Plasma drug concentrations were obtained at
ﬁve time points across 24 weeks, with predose samples
measured approximately every 4 weeks (weeks 4, 8, 14, 20,
and 24 after the start of therapy). All studies were conducted
in accordance with the principles described in the Declaration
of Helsinki (1946) up to and including the Seoul revision (20).
All clinical protocols were approved for each site by an
appropriate institutional review board, and all patients
provided written informed consent prior to participation.
Exenatide Analytical Method
Plasma samples were analyzed for exenatide concentra-
tion using a validated two-site sandwich enzyme-linked
immunosorbent assay. The capture monoclonal antibody is
speciﬁc for exenatide, as it recognizes a C-terminal epitope
and does not cross-react with GLP-1(7-36) or glucagon. The
detection monoclonal antibody recognizes an N-terminal
epitope on exenatide, GLP-1(7-36), and glucagon. The assay
is speciﬁc for exenatide due to the selectivity of the capture
antibody. Since both antibodies need to recognize the peptide
in order to generate a signal for this assay, cross-reactivity
with other peptides or metabolites is minimized. No cross-
reactivity was observed with 1 ng/mL of exendin-4(2-39),
exendin-4(3-39), GLP-1(7-36), glucagon, or insulin. The assay
lower limit of quantiﬁcation was 10 pg/mL. Method validation
speciﬁcations for accuracy, precision, and other performance
parameters associated with regulated ligand-binding assays
were met at all analytical laboratories (21).
PK Model Development
The PK model was developed in two stages, starting with
single-dose data to describe the three phases of exenatide
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release from the microspheres. Subsequently, the single- and
multiple-dose data were combined and modeled simulta-
neously. The ﬁnal PK model is shown in Fig. 1. The
absorption of exenatide from the ER formulation was
described with three distinct processes. The initial release
was captured with a ﬁrst-order absorption rate constant (ka),
whereas the second and third release processes were each
described with a series of transit compartments using an
explicit equation derived for such systems (22, 23):
dAc
dt
¼ Dose⋅ f rel⋅ f 1⋅ka⋅e−ka⋅t þ
X2
i¼1
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The estimated parameters associated with the two transit
compartment models were the number of transit compartments
(N1 and N2) and the ﬁrst-order transit rate constants (ktr1 and
ktr2). The sum of the bioavailability of the three parallel
absorption processes was parameterized to assure that all of
the bioavailable dose relative to the IR formulation (frel) is
absorbed: f3 = 1 − (f1 + f2). For each of the transit series, the
absorption rate constant from the ﬁnal transit compartment into
the central compartment is set equal to the ktr of that series.
Owing to the complex absorption kinetics, the disposition-
related population parameters (i.e., clearance (CL), Michaelis–
Menten constants (Vmax andKm) and volumes of the central and
peripheral compartments (VC and VP)) were ﬁxed to the
previously developed population model for the IR formulation
of exenatide (Cirincione B, Mager DE. Population pharmaco-
kinetics of exenatide. Manuscript accepted).
Data Analysis
All modeling and simulations were conducted using the
Laplacian estimation method within the nonlinear mixed-
effects modeling software program NONMEM version 7.2
(ICON Development Solutions, Ellicott City, MD). Interin-
dividual variability (IIV) was estimated using a log-normal
distribution model on two of the ﬁrst-order rate constants (ka
and ktr2) and the fraction of the bioavailable dose in the initial
release (f1). Alternative distribution models and IIV param-
eters were evaluated and found to be unsuccessful. The
residual variability (RV) was described with a log error
structure, and alternative RV structures were evaluated but
did not improve model performance.
The single-dose model was adapted to accommodate the
weekly dosing regimen in NONMEM using recently pub-
lished methodology for modeling multiple-dose transit com-
partment models (23). With the addition of the multiple-dose
data, an IIV term was added to the relative bioavailability
compared to the IR formulation (frel). The RV was estimated
separately for the single- and multiple-dose trials. Model
adequacy was assessed by parameter precision, standard
graphical assessments, and evaluation of predictive perfor-
mance through visual predictive checks (VPCs). The VPC
was performed by evaluating the median and 90% prediction
interval of 500 simulations from the model in comparison to
the observed data (24).
The number of samples obtained following single-dose
administration with exenatide concentrations BLQ (10 pg/
mL) was largest at the lowest dose level and generally
decreased with increasing dose. There were 83 (36.9%), 32
(15.6%), 50 (19.8%), and 26 (14.2%) samples that were BLQ
for the 2.5-, 5-, 7-, and 10-mg dose groups, respectively. The
BLQ concentrations were primarily in the time period
between the ﬁrst- and second-phase release (within the ﬁrst
5 days), which is during the lag period for hydration of the
microsphere, and at the end of the single-dose proﬁle (i.e.,
after 60 days following a single dose). Given the number of
concentrations that were determined to be BLQ and the time
dependency of their occurrence (primarily occurring between
the ﬁrst and second phases), the BLQ data were considered
informative and included in the modeling using the Beal M3
method coupled with Laplacian estimation (25). This method
allows the BLQ data to be maintained in the dataset but
treats them as censored observations (25). VPCs of the
Fig. 1. Structural PK model diagram. Exenatide PK was characterized using a two-compartment model with three absorption processes (ﬁrst-
order release and two transit compartment processes) and both linear and nonlinear elimination
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frequency of BLQ observations across time were generated
(26), in which the simulated median and 90% prediction
interval of the fraction of data predicted to be BLQ from 500
simulations were compared with the observed fraction of
observed BLQ at each time point. With the weekly dosing
regimen, the number of concentrations determined to be
BLQ was reduced to 16.3 and 9.1% for the 0.8- and 2-mg
weekly dosing regimens, and these occurred primarily at the
end of the 12-week washout period. All BLQ samples were
also included in the combined analysis.
Model Qualification
Data associated with the 2-mg dose group collected in a
phase III multiple-dose study (19) were utilized as an external
validation dataset. The prediction error (PE) and absolute
prediction error (APE) were calculated to evaluate the bias
and precision of the predicted exenatide concentrations:
PEi j ¼ Obsi j−Predi jObsi j
 
APE ¼ PEi j
 
with PREDij being the individual predicted concentration for
patient i at time point j, and Obs being the measured
concentration for the ith patient at the jth time point. In
addition, the predictive performance of the model was
assessed using VPCs (24).
RESULTS
Patient Demographics
Data were available from a total of 64 patients; 42% were
female. The mean (standard deviation) age was 53.5 years (9.8),
body weight was 95.7 kg (21), and estimated glomerular ﬁltration
rate was 89.6 mL/min/1.73 m2 (23.2). Table I summarizes the
patient demographics stratiﬁed by the single- and multiple-dose
trials. Given the small number of patients relative to the
complexities of the model, the inﬂuence of patient covariates on
the absorption parameters for the PK model was not assessed.
Single-Dose PK
Scatterplots of the observed concentrations, as a function of
time and stratiﬁed by dose, show the three phases of exenatide
release and absorption from the SC microspheres (Fig. 2). The
VPC for single-dose PK proﬁles is shown in Fig. 3 (left panels)
and conﬁrms that the model predicts the observed data well,
describing all three phases of release from the microspheres
across the dose range studied. The right panels in Fig. 3 show the
90%prediction interval for the fraction of BLQdata simulated to
occur at each time point (shaded regions), with the solid line
reﬂecting themedian simulated fraction of BLQdata at each time
point. The use of the M3 method successfully predicted the
frequency and the time course of the BLQ data with most of the





Total (n = 64) External validation
(n = 119)
Sex, n (%)
Male 20 (48.8) 17 (73.9) 37 (57.8) 70 (58.8)
Female 21 (51.2) 6 (26.1) 27 (42.2) 49 (41.2)
Race, n (%)
White 10 (24.4) 14 (60.9) 24 (37.5) 78 (65.5)
Black 5 (12.2) 2 (8.7) 7 (10.9) 6 (5.0)
Asian 4 (9.8) 1 (4.3) 5 (7.8) 5 (4.2)
Hispanic 19 (46.3) 5 (21.7) 24 (37.5) 30 (25.2)
Other 3 (7.3) 1 (4.3) 4 (6.3) –
Renal group, n (%)
Normal 16 (39.0) 7 (30.4) 23 (35.9) 56 (47.1)
Mild 22 (53.7) 16 (69.6) 38 (59.4) 54 (45.4)
Moderate 3 (7.3) N/A 3 (4.7) 8 (6.7)
Age (years)
Mean (SD) 52.7 (8.71) 55.0 (11.5) 53.5 (9.78) 56.4 (11.3)
Min–max 30–66 35–72 30–72 23–83
Weight (kg)
Mean (SD) 89.5 (18.7) 106.9 (20.3) 95.7 (21) 97.9 (20.9)
Min–max 59–131 70–155 59–155 56–159
eGFR (mL/min/1.73 m2)
Mean (SD) 88.7 (23.6) 91.2 (23.1) 89.6 (23.2) 82.3 (21.7)
Min–max 56–153 60–169 56–169 38–152
eGFR estimated glomerular ﬁltration rate, ER extended release, NA not available, SD standard deviation
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Fig. 2. Concentration versus time stratiﬁed by single SC doses of ER exenatide. Panel labels (2.5, 5,
7, and 10 mg) indicate the SC doses administered. Circles represent observed concentrations, and
solid lines connect the median concentration at each of the scheduled time points
Fig. 3. VPCs for the single-dose model (left panels) and the fraction of BLQ concentrations
predicted by time (right panels) and stratiﬁed by dose group. Row panel labels (2.5, 5, 7, and 10 mg)
indicate the administered SC single doses. Circles depict observed concentrations from the single-
dose study. Dashed red lines connect the medians of the observed data for time points where >50%
of the data is above the BLQ. Black solid lines represent the median of the predicted data. Shaded
gray regions are the 90% prediction intervals
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observed data located within the 90% prediction interval. A
comparison of the observed and predicted time-course of
exenatide plasma concentrations in representative patients is
shown in Fig. 4, further illustrating the range of concentrations
and phases of release captured by the model. Together, these
ﬁgures suggest that the model adequately describes the central
tendency and variability of the PKproﬁles across all doses, as well
as provide a robust prediction of the fraction and time-course of
the appearance of BLQ samples.
All model parameters were estimated well (% relative
standard error (RSE) <40%) (Table II) with low magnitude of
shrinkage (16%) on all IIVand RV terms. IIV was not allowed on
the number of transit compartments to maintain the structural
model across patients; of the remaining seven estimated param-
eters, only two did not include IIV. Themajormodel permutations
and associated outcomes are listed in Supplementary Table S1.
Previously identiﬁed covariate relationships were ﬁxed, including
renal function on CL and body weight on VC (Table II). The
overall relative bioavailability of a single dose of the ER
formulation relative to the IR formulation was estimated at
10.2%, with the bioavailable dose distributed across the three
absorption processes.Only 1%of the available dosewas estimated
to be absorbed during the initial-release phase, with approximately
46 and 53% of the remaining available dose being absorbed
through the transit compartment pathways (transit series 1 and 2,
respectively). The mean (%RSE) absorption rate constant for the
initial release (ka) was estimated to be 2.98 days
–1 (14.7%). For the
ﬁrst series of transit compartments, the mean transit time was
approximately 19 days (∼3 weeks), corresponding well with the
observed time of the second drug concentration peak. The second
series of transit compartments supported an estimated mean
transit time of approximately 46 days (∼7 weeks), corresponding
with the third phase of drug release (Fig. 4).
Combined Single- and Multiple-Dose Modeling
Prediction of the multiple-dose data using the single-dose
model adequately described the shape of the concentration–
time proﬁles but showed a slight underprediction of the
steady-state concentrations (data not shown). Estimation of
the model parameters for the combined dataset did not
meaningfully alter the parameter estimates obtained from the
single-dose data alone. For the combined analysis, separate
relative bioavailability terms were estimated for the single-
and multiple-dose studies. The estimated relative bioavail-
ability for the phase II clinical trial was greater than for the
phase I clinical trial (15.5% versus 8.86%) (Table II). All
parameters were estimated well (Table II, RSE < 40%), and
the magnitude of shrinkage was low (<23% on all IIV and RV
parameters). The model adequately describes the rise to
steady-state concentrations, with steady-state predicted to
occur after 6–10 weeks of treatment, and the subsequent
decline to undetectable concentrations 10–12 weeks after
stopping drug administration (Fig. 5).
Table II. Final Model Parameter Estimates and Standard Errors for the Single-Dose and the Combined Single- and Multiple-Dose Models
Parameter Single-dose model Combined single- and multiple-dose models
Parameter estimate %RSE IIV (%) %RSE Parameter estimate %RSE IIV (%) %RSE
ka (1/day) 2.98 14.7 77.9 23.9 3.85 11.2 53.9 37.6
CLint (L/day) 110 NE – – 110 NE – –
Vcint (L) 7.03 NE – – 7.03 NE – –
f1 (%) 1.13 12.5 83 34.5 1.18 8.56 66.7 23.4
f2 (%) 46.3 9.05 – – 48.0 8.77 – –
f3 (%) 52.6 NE – – 50.8 NE
frel(single-dose study) (%) 10.2 7.61 – – 8.86 7.56 43.8 20.1
frel(Mdstudy) (%) NA – – – 15.5 5.93
ktr1 (1/day) 0.0872 8.92 – – 0.105 9.50 – –
N1 0.667 22.6 – – 0.570 17.2 – –
ktr2 (1/day) 0.722 15 13.6 27 0.591 17.9 17.2 20.9
N2 32.2 15.5 – – 26.1 19.6 – –
Vcwtkg 2.67 NE – – 2.67 NE – –
CLeGFR 0.838 NE – – 0.838 NE – –
Km (pg/mL) 567 NE – – 567 NE – –
Vmax (mg/day) 0.037 NE – – 0.0372 NE – –
CLd (L/day) 89.3 NE – – 89.3 NE – –
VP (L) 7.04 NE – – 7.04 NE – –
RVSD Study (Log SD) 0.727 4.08 – – 0.684 4.58 – –
RVMD Study (Log SD) NA – – – 0.376 4.57 – –
CL clearance, CLd distributional clearance, CLeGFR power for eGFR effect on linear clearance, CLint linear elimination rate for patient with
eGFR of 80 mL/min/1.73 m2 , eGFR estimated glomerular ﬁltration rate, f1, f2, f3 bioavailability of each parallel absorption process,
frel bioavailable dose relative to immediate-release formulation, IIV inter-individual variability, ka ﬁrst-order absorption rate constant,
Km concentration required for half of the nonlinear elimination rate (Vmax), ktr1 and ktr2 ﬁrst-order transit rate constants, N1 and N2 number
of transits, NA not available, NE not estimated, RSE relative standard error, RV residual variability, SD standard deviation, SE standard
error, VC volume of central compartment, Vcint volume of the central compartment for an 84.8 kg person, Vmax maximum nonlinear elimination
rate constant, Vcwtkg power for weight effect on volume of the central compartment, VP volume of peripheral compartment
CL ¼ CLint⋅ eGFR80
 
CLeGFRVC ¼ Vcint⋅ weight84:8
 	Vcwtkg
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External Model Qualification
The ﬁnal PK model was used to predict the concentra-
tions collected in a phase III trial of ER exenatide adminis-
tered at 2 mg once weekly. The model predicted the
exenatide concentration–time proﬁle from the phase III study
with high ﬁdelity as assessed by visual assessment (Fig. 6).
The observed and predicted proﬁles show large variability,
and the good alignment of the observed and predicted
median exposures conﬁrms the predictive performance of
the model. Assessment of the PEs further suggests that the
model is reasonably accurate in predicting exenatide concen-
Fig. 4. Comparison of observed and predicted PK proﬁles. Panel labels (2.5, 5, 7, and 10 mg)
indicate the administered SC doses. Circles depict observed concentrations from the single-dose
study, and solid lines represent population mean estimated proﬁles. Dashed lines represent
individual estimated curves following a single SC dose of ER exenatide in representative patients
Fig. 5. VPCs for multiple-dose proﬁles and the fraction of concentrations that are BLQ. Row panel
labels (0.8 and 2.0 mg) indicate the administered SC doses. Circles depict observed concentrations
from the multiple-dose study. Dashed red lines connect the medians of the observed data for time
points where >50% of the data is above the BLQ. Black solid lines represent the median of the
predicted data. Shaded gray regions are the 90% prediction intervals. Arrows indicate weekly
administered doses
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trations with a median PE% of –1.85% across all time points.
The median absolute PE was 25%, illustrating that the model
shows adequate precision on an individual level.
DISCUSSION
The sustained release of exenatide was achieved by the
dispersion of exenatide within PLGA microspheres, such that
the active peptide that is released and absorbed into the
circulation following SC administration is identical to that
found in the IR formulation (17). In terms of the PK
properties (absorption, distribution, and elimination) of the
ER formulation, only the absorption-related properties differ
from the IR formulation. A population PK model of the IR
formulation was developed to quantify the inﬂuence of weight
and renal function, as well as the linear and nonlinear
elimination components (Cirincione B, Mager DE. Popula-
tion pharmacokinetics of exenatide. Manuscript accepted).
This model served as the foundation for the development of
the PK model of the ER formulation, which was expanded to
include a complex absorption system described by three
parallel processes.
Previous PK modeling of the ER formulation of
exenatide focuses solely on estimating the steady-state
concentrations and evaluating the intrinsic factors that
inﬂuence such values (27). Although useful in describing
the exenatide exposure–response relationships, the model is
limited to steady-state conditions. Thus, the model devel-
oped herein provides a tool that quantiﬁes not only steady
state but also the ability to evaluate the time to steady-state
and decrease in drug concentrations upon cessation of
therapy, which are important clinical considerations when
assessing the time to achieve effective clinical response and
the time it takes to wash out the drug after halting therapy.
The ﬁnal PK model incorporates BLQ measurements
using the M3 method (25). During the initial stages of model
development, the BLQ concentrations were excluded and
resulted in minimization difﬁculties. The dissolution of the
microsphere is known to have periods of time with minimal
release, thus resulting in two main sections of the typical
concentration–time proﬁle where BLQ concentrations oc-
curred. The ﬁrst appearance is between Day 1 and 1 week
following drug administration. This phase reﬂects the lag time
that occurs between the initial release and the second-phase
release (i.e., microsphere hydration) (17), with the other
occurrence within the terminal elimination phase. Thus, the
incorporation of the BLQ measurements was critical for
adequately capturing each phase of drug release.
The microsphere technology has been used with other
injectable ER products. Absorption kinetics for these prod-
ucts can also be complex and are commonly comprised of an
initial release followed by a longer sustained-release proﬁle.
The speciﬁc release characteristics can be customized to
maximize unique therapeutic goals. Several PK modeling
approaches have been reported for these products, including
initial deconvolution techniques to identify speciﬁc absorp-
tion rate constants for subsequent use in a PK model (28), as
well as the estimation of combinations of sequential dual and
triple ﬁrst-order absorption rate constants and associated lag
times (29, 30). The use of transit compartments to capture the
delay in absorption processes has been reported (22, 23), and
we utilized two series of transit compartments to describe the
delays in the system associated with the second and third
phases of drug release. The absorption of a long-acting
formulation of risperidone from a PLGA implant was also
characterized using a similar series of transit compartments,
and a ﬁrst-order process was included for the initial drug
release (31). In contrast to modeling the absorption proﬁle
Fig. 6. VPC for phase III external validation. Circles depict observed concentrations from
the phase III external validation study. Dashed red line represents the median of the
observed data. Dashed black lines represent the 5th and 95th percentiles for the observed
data. Black solid line represents the median of the predicted data. Shaded gray regions
represent the 90% prediction interval around the median and 5th and 95th percentiles
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with estimated absorption rate constants and lag times, this
approach provides a more gradual input into the central
compartment, resulting in a proﬁle that is more representa-
tive of the observed exposure proﬁles for ER formulations.
Although the use of transit compartments is empirical and
simpliﬁes the release and absorption processes that occur
from the microspheres, it was found to capture the three
distinct peaks of plasma exenatide concentrations well, thus
allowing for simulations that will accurately describe the rise
to steady-state and better predict plasma exenatide concen-
trations under various conditions, such as missed doses and
incomplete dosing.
The appearance of antidrug antibodies to exenatide has
been reported (32), and a retrospective analysis of the
immunogenic response to exenatide showed that the peak
immune response occurs at 6–22 weeks and subsequently
decreases (32). The binding of the antibody to the peptide
prevents the renal clearance of exenatide; however, the
inﬂuence of antibodies on the elimination of exenatide has
not been evaluated in the IR model. Additional data are
needed to evaluate the effect of antibody titer on total
systemic clearance. The incidence of antidrug antibodies has
been reported to be greater with the ER formulation than
with the IR formulation, and further analysis of the potential
effect on both formulations is warranted.
CONCLUSIONS
In summary, a population-based PK model was success-
fully developed for an ER formulation of exenatide. Since the
prolonged exenatide release is achieved by drug dispersion in
PLGA microspheres, an ER proﬁle is accomplished without
alteration of the exenatide peptide. This allows the model to
reconcile the PK properties of the ER and IR formulations
and should also serve as a platform for studying subsequent
pharmacodynamic properties. The enhanced features of this
model facilitate addressing critical clinical questions, includ-
ing the effects of intrinsic factors on the time to steady-state,
steady-state exposure, and the time at which concentrations
become undetectable after cessation of therapy.
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